Cue Biopharma, Inc. (CUE)

NASDAQ: CUE · USD

$21.2

+2.84 (+15.5%)· Recorded snapshot

Market cap	153.7M
Revenue (ttm)	37.7M
Net income (ttm)	-164.1M
EPS (ttm)	-$36.2
Shares out	7.3M
Volume	127,262
Beta	2.63

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 37.7M
Net income (ttm): -164.1M
EPS (ttm): -$36.2
Market cap: 153.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-1,603.5

P25 -113.8P50 -46.5P75 -0.9

ROIC-395.5

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All CUE indicators

Market & fundamental data

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001645460
Company name	Cue Biopharma, Inc.
Country	United States
Country code	US
CUSIP number	22978P205
Earnings date	2026-11-11
Earnings time	amc
Employees	29
Employees change	-12
Employees growth	-29.27%
Enterprise value	$139.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
Industry	Biotechnology
IPO date	2018-01-02
Is primary listing	Yes
Is SPAC	No
ISIN number	US22978P2056
Last 10-K release date	2026-03-16
Last earnings date	2026-08-14
Last refreshed	2026-10-28
Last stock split date	2026-04-24
Last stock split type	Reverse
Market cap	$153.7M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$21.16
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CUE
U.S. state	Massachusetts
Website	https://www.cuebiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-171.18%
EV/Sales	3.74x
FCF / EV yield	-35.6%
FCF yield	-32.32%
Forward EV/Sales	69.3x
Forward P/S	76.35x
P/B ratio	41.47x
P/S ratio	4.12x
Price / tangible book value	67.2x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-261.97%
EBITDA margin	-258.36%
Gross margin	-99.15%
Operating margin	-261.97%
Pretax margin	-434.49%
Profit per employee	$-5.7M
Revenue per employee	$1.3M
ROA	-172.66%
ROA (5Y)	-42.14%
ROCE	-1,039.56%
ROE	-1,603.48%
ROE (5Y)	-102.17%
ROIC	-395.46%
SBC / revenue	69.12%
Tax / revenue	1.33%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	3
Revenue growth	354.44%
Revenue growth (Q)	166.66%
Revenue growth (QoQ)	38.53%
Revenue growth 3Y	176.1%
Revenue growth 5Y	47.08%
Revenue growth quarters	3
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-121,000
Depreciation and amortization	$1.4M
EBIT	$-98.6M
EBITDA	$-97.3M
EPS	$-36.22
FCF per share	$-6.91
Financing cash flow	$39.8M
Free cash flow	$-50.2M
Free cash flow minus SBC	$-76.2M
Gross profit	$-37.3M
Income taxes	$500,000
Investing cash flow	$131,000
Net borrowing	$-2.5M
Net cash flow	$-10.1M
Net income	$-164.1M
Operating cash flow minus SBC	$-76.1M
Operating income	$-98.6M
Revenue	$37.7M
Stock-based compensation	$26M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-32
Book value per share	$0.44
Debt / equity	1.33
Interest coverage	-508.47
Long-term assets	$4.1M
Long-term liabilities	$7.2M
Net cash (debt)	$14.3M
Net cash / market cap	9.24%
Net cash growth	-29.47%
Net debt / equity	-6.21
Piotroski F-Score	3
Property, plant and equipment	$3.2M
Shareholders' equity	$2.3M
Tangible book value	$2.3M
Tangible book value per share	$0.44
Total assets	$30.7M
Total cash	$17.4M
Total debt	$3.1M
Total liabilities	$28.4M
WACC	18.44%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.05
Current assets	$26.6M
Current liabilities	$21.2M
Current ratio	1.25
Net working capital	$-10.4M
Quick ratio	1.07
Working capital	$5.4M
Working capital turnover	4.43

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-84.06%
Dividend yield	0%
Shareholder yield	-84.06%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$24.97
1D price change	15.5%
1M price change	-32.63%
1M total return	-32.63%
1W price change	11.66%
1W total return	11.66%
1Y price change	-8.45%
1Y return CAGR	-8.45%
1Y total return	-8.45%
20-day SMA	$20.83
200-day SMA	$21.04
3M price change	-35.03%
3M total return	-35.03%
3Y price change	-60.6%
3Y return CAGR	-26.68%
3Y total return	-60.6%
50-day SMA	$25.69
50-day SMA vs 200-day SMA	50over200
52-week high	$45.50
52-week high date	2026-07-10
52-week low	$4.97
52-week low date	2026-04-06
5Y price change	-94.19%
5Y return CAGR	-43.39%
5Y total return	-94.19%
6M price change	18.02%
6M total return	18.02%
All-time high	$950.70
All-time high date	2020-05-26
All-time low	$4.97
All-time low date	2026-04-06
Average true range (ATR)	$2.75
Average volume	173K
Beta (1Y)	6.63
Beta (2Y)	3.22
Beta (5Y)	2.63
Change from 52-week high	-53.49%
Change from 52-week low	325.67%
Change from all-time high	-97.77%
Change from all-time low	325.67%
Change from open	12.67%
Day's gap	2.51%
Dollar volume	$2.7M
High price	$21.71
Low price	$18.78
Monthly RSI	42.38
Open price	$18.78
Position in 52-week range	81.23%
Premarket change	2.62%
Premarket close	$18.32
Premarket price	$18.80
Previous close	$18.32
Price vs 150-day SMA	-15.25%
Price vs 20-day SMA	1.6%
Price vs 200-day SMA	0.56%
Price vs 50-day SMA	-17.65%
Relative volume	0.74
RSI	47.41
Sharpe ratio	0.75
Sharpe ratio (3Y)	0.4
Sharpe ratio (5Y)	0.06
Sortino ratio	1.66
Sortino ratio (3Y)	0.85
Sortino ratio (5Y)	0.17
Volume	127.3K
Weekly RSI	46.97
YTD price change	130.95%
YTD total return	130.95%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6.4M
Float percentage	87.57%
Shares change (QoQ)	31.9%
Shares change (YoY)	84.06%
Shares held by insiders	7.34%
Shares held by institutions	22.71%
Shares outstanding	7.3M
Short % of float	12.46%
Short % of shares	10.91%
Short ratio	1.7 days

Deeper analysis on CUE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CUE report

Is a complete CUE research report available?

No complete published report is available for Cue Biopharma, Inc. (CUE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cue Biopharma, Inc. (CUE)

Price

Financial snapshot

Fair-value bridge

Latest news · CUE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CUE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CUE

Frequently asked questions